Loading patent…
AssigneeAkeso Biopharma, Inc.
InventorsBaiyong LI, Yu XIA, Zhongmin Maxwell WANG, Peng ZHANG
Estimating the term…
The present invention relates to the fields of treating autoimmune diseases and molecular immunology, and specifically, to an anti-IL-17A antibody, a pharmaceutical composition thereof, and use thereof. More specifically, the present invention relates to a monoclonal antibody or an antigen binding fragment thereof, wherein a heavy chain variable region of the monoclonal antibody comprises: HCDR1-HCDR3 with amino acid sequences set forth in SEQ ID NOs: 31-33 respectively, or HCDR1-HCDR3 with amino acid sequences set forth in SEQ ID NOs: 37-39 respectively, and a light chain variable region of the monoclonal antibody comprises: LCDR1-LCDR3 with amino acid sequences set forth in SEQ ID NO: 34, KVS, and SEQ ID NO: 36, respectively, or LCDR1-LCDR3 with amino acid sequences set forth in SEQ ID NO: 40, LVS, and SEQ ID NO: 42, respectively. Monoclonal antibodies of the present invention can specifically bind to IL-17A, specifically antagonize the binding of IL-17A to a ligand thereof, and inhibit activation of fibroblasts by IL-17A.
An isolated nucleic acid molecule comprising one or more nucleic acid sequences encoding an anti-interleukin-17A (anti-IL-17A) monoclonal antibody or antigen-binding fragment thereof comprising:
A hybridoma cell line LT006, which was deposited at China Center for Type Culture Collection (CCTCC) with the accession number of CCTCC NO:
A method of treating an autoimmune disease in a subject in need thereof, comprising administering to the subject an effective amount of an anti-IL-17A monoclonal antibody or an antigen-binding fragment thereof comprising:
An anti-IL-17A monoclonal antibody or an antigen-binding fragment thereof comprising:
Dependencies are inferred from the claim text.